Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Triphalangeal thumbs-brachyectrodactyly syndrome is characterized by triphalangeal thumbs and brachydactyly of the hands. It has been described in four families and in one isolated case. Ectrodactyly of the feet and, more rarely, ectrodactyly of the hands were also reported in some family members. Transmission is autosomal dominant.
Features include: Triphalangeal thumb, Short 3rd toe, Brachydactyly, and Split foot and 2 more.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Arms and legs | 4 | Short 3rd toe, Split foot, Split hand |
Biomarker and diagnostic research for triphalangeal thumbs-brachyectrodactyly syndrome has been reported in the published literature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for triphalangeal thumbs-brachyectrodactyly syndrome.
103 publications have been identified in PubMed for triphalangeal thumbs-brachyectrodactyly syndrome. Research spans Epidemiology / Natural History (29%), Review / Meta-Analysis (20%), and Basic Science / Preclinical (17%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 30 | 29% |
Data assembled from 5 of 12 sources · Last updated Sep 18, 2026, 1:26 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Research summaries |
21 |
20% |
Laboratory research | 17 | 17% |
Clinical study results | 15 | 15% |
Patient case studies | 8 | 8% |
Testing and diagnosis research | 7 | 7% |
New treatment approaches | 3 | 3% |
Other research | 2 | 2% |
Kuipers RN (2026). [PMID: 42018196](https://pubmed.ncbi.nlm.nih.gov/42018196/). *Fam Cancer*. [Review / Meta-Analysis]
Khalil M (2026). [PMID: 41994701](https://pubmed.ncbi.nlm.nih.gov/41994701/). *Cureus*. [Case Report / Case Series]
Mansur A (2026). [PMID: 28613628](https://pubmed.ncbi.nlm.nih.gov/28613628/). *Unknown Journal*. [Basic Science / Preclinical]
Hönes GS (2026). [PMID: 42078357](https://pubmed.ncbi.nlm.nih.gov/42078357/). *medRxiv*. [Basic Science / Preclinical]
Castillo-Córdoba EM (2026). [PMID: 42067462](https://pubmed.ncbi.nlm.nih.gov/42067462/). *J Clin Lipidol*. [Review / Meta-Analysis]
Ramirez-Gamero A (2026). [PMID: 41118612](https://pubmed.ncbi.nlm.nih.gov/41118612/). *Blood Adv*. [Epidemiology / Natural History]
Castillo J (2026). [PMID: 41968832](https://pubmed.ncbi.nlm.nih.gov/41968832/). *J Gerontol A Biol Sci Med Sci*. [Review / Meta-Analysis]
Labetoulle M (2026). [PMID: 41314967](https://pubmed.ncbi.nlm.nih.gov/41314967/). *J Ocul Pharmacol Ther*. [Clinical Trial Publication]
Villa S (2026). [PMID: 41501610](https://pubmed.ncbi.nlm.nih.gov/41501610/). *Emerg Infect Dis*. [Diagnostic / Biomarker]
Zambrano K (2026). [PMID: 41045340](https://pubmed.ncbi.nlm.nih.gov/41045340/). *J Anesth*. [Review / Meta-Analysis]